natgillin/translations-raw huggingface dataset:
izraža prepričanje, da so investicije v zagotavljanje vode, boljših zdravstvenih in higienskih razmer ter infrastrukture na eni strani in dvigovanje zavesti o povezavi med zdravjem, čisto vodo, zdravstvenimi razmerami in higieno na drugi bistvenega pomena pri odpravljanju bolezni, ki se prenašajo z okuženo vodo (med njimi pljučnica, driska, malarija) in delovanju zdravstvenih sistemov;
Believes that investment in water supply, sanitation and infrastructure as well as raising awareness of the links between health, clean water, sanitation and hygiene are critical to combating waterborne diseases (including pneumonia, diarrhoea, malaria) and to the delivery of healthcare systems;
poziva, da se v dokument o človeških virih v okviru akcijskega programa Komisije vključijo tudi predlogi za nujno ukrepanje na področju pomanjkanja zdravstvenih delavcev v državah v razvoju z zagotavljanjem boljšega usposabljanja, poklicnih možnosti, plačila, pobud za to, da ne odhajajo drugam, varnih delovnih pogojev, sodelovanja v posebnih pobudah s področja bolezni, partnerskega sodelovanja, prostovoljne podpore in širjenja dobre prakse in tehnične podpore;
Calls for the policy document on human resources provided for in the Commission's Programme for Action also to include proposals for urgent action to reverse the loss of health workers from developing countries, such as better training, career opportunities, remuneration, retention incentives, safe working conditions, cooperation with disease-specific initiatives, twinning arrangements, voluntary support and the spread of best practice and technical support;
poudarja potrebo po usklajenem delovanju v sami EU ter med EU in drugimi mednarodnimi in lokalnimi donatorji, da bi na ta način združili potrebno strokovno znanje in si delili tehnično pomoč, kar bi doprineslo k boljšim rezultatom;
Stresses the need for coordination within the EU and between the EU and other global and local donors, to pool expertise and share technical assistance in order to improve outcomes;
pozdravlja zavezo Komisije, da krepi zmogljivosti držav v razvoju pri izvajanju raziskav, vseeno pa poziva, da raziskave razširijo tako, da poleg kliničnih testiranj vključujejo tudi raziskave na področju operativnih in zdravstvenih sistemov, saj so zelo pomembne za razvoj učinkovitejšega, uspešnejšega in trajnejšega izvajanja intervencij;
Welcomes the Commission's commitment to strengthening the capacity of developing countries to conduct research, but calls for this to extend beyond clinical trials to a broader concept of research that includes operational and health systems research so important in developing more effective, efficient and sustainable implementation of interventions;
poudarja, da so za zagotovitev učinkovitih intervencij, projektov in programov potrebne najboljše prakse v znanstvenem raziskovanju in izvajanju;
Emphasises that best practice in scientific research and implementation are needed to ensure effective interventions, projects and programmes;
ugotavlja, da bi bilo treba posebno skrb posvetiti načinu izdajanja in uporabe zdravil, da bi omejili odpornost;
Notes that care should be taken in the way that medicines are dispensed and used in order to limit resistance;
ugotavlja, da je po cunamiju, ki je pretresel Azijo, prekinitev zdravljenja malarije, tuberkuloze ali antiretrovirusnega zdravljenja povzročila veliko smrtnih žrtev;
Notes that, as a result of the Asian tsunami, the interruption of malaria, TB or ARV treatment there could cause many deaths;
pozdravlja rezultate Eurobarometra, ki kažejo, da javno mnenje v EU ocenjuje pomoč EU kot najučinkovitejšo v boju proti aidsu in drugim boleznim Posebni Eurobarometer 222, Odnos do razvojne pomoči, februar 2005.
Welcomes the Eurobarometer results showing that the EU public believes that EU aid can be most effective in the fight against AIDS and other diseases Special Eurobarometer 222, Attitudes towards Development Aid, February 2005.
poudarja potrebo po dostopu do zdravil in po tem, da farmacevtska podjetja izdelujejo zdravila, ki bodo po dostopni ceni na voljo v državah z nizkimi dohodki;
Stresses the urgency of access to medicines and for pharmaceutical producers to make drugs available and affordable in low income countries;
izpostavlja pomen pobud in odgovornega ravnanja držav in Komisijo poziva, da zagotovi tvorno sodelovanje prizadetih skupnosti in civilne družbe pri tem procesu, saj bodo le na ta način akcijski okviri dejansko odsevali dvome in izkušnje marginaliziranih skupnosti;
Stresses the importance of country leadership and accountability and calls on the Commission to ensure that affected communities and civil society are meaningfully involved in this process to ensure that Action Frameworks reflect the concerns and experiences of marginalised communities;
poziva Komisijo, da oceni dejanski vpliv ukrepov, ki se izvajajo v okviru Uredbe (ES) št. 953/2003, farmacevtsko industrijo pa, da ponudi proizvode z vzporedno oblikovano ceno in s tem prispeva k boljšemu dostopu do temeljnih zdravil za ljudi iz držav v razvoju, v primeru pomanjkanja pa da predlaga dodatne ukrepe za omogočanje dostopa zlasti do osnovnih zdravil;
Calls on the Commission to assess the real impact of the measures implemented under Regulation (EC) No 953/2003 and on the pharmaceutical industry to make products available to the people of developing countries at tiered prices for improving access to essential medicines, and to propose complementary measures to enable access specifically to essential medicines if shortages exist;
poziva Komisijo, naj z oblikovanjem foruma zainteresiranih strani ES vzpostavi sistematični in redni način posvetovanja s civilno družbo, ljudmi, okuženimi z HIV/aidsom, malarijo in tuberkulozo ter predstavniki civilne družbe iz držav v razvoju;
Calls on the Commission to use the EC Stakeholder Forum as a systematic and regular mechanism of consultation with civil society, people affected by HIV/AIDS, malaria and TB and representatives of community-based organisations from developing countries;
opozarja Komisijo na pomembno vlogo žensk v osnovnem zdravstvenem varstvu in na dejstvo, da je treba ženske, otroke in invalidne osebe vključiti v zdravstveno politiko, ustrezno statistiko in raziskave;
Reminds the Commission of the importance of women in primary health care and that women, children and people with disabilities need to be mainstreamed into health policies and related statistics and research;
pozdravlja podporo, ki jo Komisija v svojem akcijskem programu namenja celovitim in strokovno podprtim preventivnim programom in jo poziva k podpiranju programov za preprečevanje okužbe s HIV/aidsom, ki naj vključujejo politično angažiranje, izobraževanje s ciljem doseganja vedenjskih sprememb, programe za odpravljanje prizadejane škode, razdeljevanje osnovnih proizvodov, prostovoljno svetovanje in testiranje, oskrbo z varno krvjo, ukrepe za večjo odpornost pred okužbami za skupine, ki veljajo za bolj dovzetne za infekcije, pa tudi družbene in vedenjske raziskave;
Welcomes the Commission's support in its Programme for Action for comprehensive and evidence-based prevention programmes, and urges the Commission to support HIV/AIDS prevention programmes which include political leadership, education to support behavioural change, harm reduction programmes, commodity distribution, voluntary counselling and testing, secure blood supply, vulnerability reduction measures for groups at higher risk of infection as well as social and behavioural research;
poudarja potrebo po večjih investicijah v raziskave in razvoj s področja novih tehnologij za preprečevanje širjenja HIV, npr. cepiv in mikrobicidov, in poziva k razvoju prilagojenih in cenovno sprejemljivih pediatričnih oblik ARV za 2,2 milijona otrok, okuženih z HIV, skupaj z diagnostičnimi in nadzornimi sredstvi, ki bodo prilagojeni potrebam in razmeram v državah v razvoju;
Stresses the need for increased investment in R&D into new technologies for HIV prevention such as vaccines and microbicides and calls for the development of adapted and affordable paediatric formulations of ARV for the 2.2 million children living with HIV, alongside diagnostic and monitoring tools suited to their needs and to developing country settings;
poziva Komisijo, naj prizna, da očitna epidemija HIV zahteva ustrezen pristop, ne glede na to ali gre za države, kjer je epidemija splošno ali le delno razširjena; hkrati mora biti večja pozornost namenjena razumevanju načina prenosa bolezni v različnih kontekstih in temu ustreznega ukrepanja;
Urges the Commission to acknowledge that distinct HIV epidemics require distinct approaches, whether this be for countries with generalised or with concentrated epidemics; and that greater attention must be given to understanding transmission patterns in each different context and acting in accordance with this evidence;
poziva, da je treba starejše osebe, sirote in druge ranljive otroke upoštevati pri politiki za zmanjševanje revščine in podpori za družine, prizadete zaradi HIV/aidsa in drugih bolezni, in da morajo le-ti biti udeleženi in sodelovati pri oblikovanju in izvajanju programov;
Calls for older people, orphans and other vulnerable children to be taken into account in policies for poverty reduction and support for families affected by HIV/AIDS and other diseases, and for their involvement and participation in the design and implementation of programmes;
poziva k vzpostavitvi tesnejših povezav med programi za spolno in reproduktivno zdravje in programi za boj proti HIV/aidsu in zagotavljanje materialov za spolno in reproduktivno zdravje, vključno z ženskimi in moškimi kondomi, ustreznimi zdravili in testi za ugotavljanje spolno prenosljivih bolezni;
Calls for a stronger linkage between sexual and reproductive health and HIV/AIDS programmes, and adequate, accessible and affordable HIV/AIDS and sexual and reproductive health related supplies, including male and female condoms and STD diagnostics and drugs;
izraža veliko zaskrbljenost nad poročili o tem, da nekatere afriške vlade obdavčujejo prodajo ali uvoz antiretroviralnih in drugih zdravil, zaradi česar so zdravila predraga za revne skupnosti; poziva Komisijo, naj to problematiko preuči in spodbuja vlade, da tovrstne davščine odpravijo;
Is very concerned at reports that some African governments are charging a sales or import tax on ARV and other drugs, which then make the drugs unaffordable to poor communities; urges the Commission to investigate this and to encourage governments to abolish such taxes;
poziva države, ki jih je prizadela malarija, da se zavežejo in pospešijo uvedbo kombiniranega zdravljenja z artemisininom (ACT, Artemisinin-based Combination Therapy), ki velja za najučinkovitejše, in poziva donatorje, da financirajo ACT in podprejo nakup, vpis na prednostni seznam in izdelavo zdravil, ki temeljijo na artemisininu;
Calls for countries affected by malaria to commit to and accelerate the introduction of Artemisinin-based Combination Therapy (ACT), recognised as the most effective treatment, calls on donors to finance ACT and support the purchase, prequalification and manufacture of artemisinin-based drugs;
poziva industrijo k izdelavi z insekticidom prepojenih mrež proti komarjem, zlasti tistih z dolgotrajnim učinkovanjem, poziva k pričetku izvajanja programov za pospešeno razdeljevanje tovrstnih mrež, programov usposabljanja za ugotavljanje simptomov malarije, programov za odpravo stoječe vode in za oskrbovanje osnovnih zdravstvenih služb z zdravili in zanesljivimi hitrimi diagnostičnimi testi ter programe za krepitev sodelovanja na ravni držav pri usklajevanju in odpravljanju možnih ozkih grl;
Calls for industry to manufacture insecticide-treated nets (ITNs), especially long lasting insecticidal nets, calls for programmes to rapidly scale up coverage of ITNs, to provide training in malaria symptoms, to remove sources of stagnant water and to equip primary health services with drugs and reliable rapid diagnostic tests, and to strengthen country-led partnerships to coordinate the scale up and to eliminate implementation bottlenecks;
meni, da so za lišmaniozo potrebni preprosti in učinkoviti diagnostični testi, prilagojeni pogojem v državah z omejenimi viri; ugotavlja, da je za raziskave in razvoj novih zdravil namenjenih premalo sredstev in da obstajajo alternativna zdravila, vendar so draga, njihova uporaba pa ni preprosta; poziva k hitri registraciji potencialno učinkovitih zdravil, kot sta paromomicin in miltefozin;
Considers that simple effective diagnostic tests are needed for leishmaniasis, suited to conditions in resource-poor countries; notes that R&D of new treatments is under-funded and that alternative drugs exist but are expensive and difficult to administer; calls for the speedy registration of promising drugs such as paromomycin and miltefosine;
upošteva delo DNDi (Drugs for Neglected Diseases Initiative) in TDR (Special Programme for Research and Training in Tropical Diseases) pri zdravljenju afriške tripanosomioze in poudarja nujno potrebno oceno varnosti in učinkovitosti nifurtimoksa in razvoj novih natančnih diagnostičnih testov, ki jih je enostavno uporabljati;
Notes the work of DNDi and TDR on a treatment for HAT, and stresses the urgent need to assess the safety and efficacy of nifurtimox, and to develop new, easy-to-use and accurate diagnostic tests;
poziva k večjim naporom pri preprečevanju šagasa z vključitvijo ciljnih populacij v nadzor nad prenosom bolezni, z ločitvijo bivalnih prostorov ljudi in živali in z zatiranjem prenašalcev z insekticidi;
Calls for increased efforts in the prevention of Chagas' disease by involving target populations in transmission control, by separating living accommodation of animals and people and by combating vectors with insecticide;
pozdravlja globalni program WHO za določitev območij, kjer je limfatična filariaza endemična, in za redno letno zdravljenje ogrožene populacije z enim odmerkom v obdobju vsaj petih let;
Welcomes the WHO Global Programme to identify districts where lymphatic filariasis is endemic and treat the at-risk population with a yearly single-dose treatment, for at least five years;
meni, da je zagotavljanje varnih in učinkovitih zdravil zelo koristno in da znašajo stroški nadzorovanja ali zdravljenja okužb z uporabo doniranih zdravil enkrat letno ali na dve leti približno 0,20 EUR na zdravljeno osebo;
Believes that there are great benefits from delivering safe and effective drugs; that controlling or eliminating infections by annual or biannual administration of donated drug interventions costs approximately EUR 0.20 per person treated;
poziva k izvajanju pobude "Quick Wins", določene v poročilu OZN 2005 o doseganju ciljev tisočletja, vključno z rednim letnim zatiranjem črevisnih parazitov;
Calls for the implementation of the "Quick Wins" identified in the report of the UN Millennium Project 2005 including regular annual deworming;
poziva EU, da sprejme konkretne ukrepe za odpravljanje revščine in zagotovi doslednost političnih ukrepov na področju trgovine, razvoja, sodelovanja in kmetijstva in na ta način prispeva k preprečevanju posrednih in neposrednih negativnih učinkov na gospodarstva držav v razvoju;
Calls on the EU to take concrete steps to counter poverty and ensure consistency between its policies in the fields of trade, development cooperation and agriculture, with a view to preventing any direct or indirect negative impact on the economies of developing countries;
poziva k večji pomoči za duševne in nevrološke bolezni in motnje, zlasti za unipolarno depresijo in epilepsije;
Calls for a new emphasis on support for mental and neurological diseases and disorders, especially unipolar depression and epilepsy;
izraža prepričanje, da bi zdravstvene službe, usposobljene za odkrivanje in zdravljenje stanj, kot je sladkorna bolezen, lahko rešile številna življenja in prispevale k manjšemu številu invalidnosti in amputacij; zlasti je treba omogočiti širši in cenovno ugodnejši dostop do inzulina in zdravil za diabetes tipa 2;
Believes that health services able to diagnose, manage and treat conditions such as diabetes would save many lives and reduce disability and amputations; in particular access to insulin and Type 2 drugs needs to be expanded and made affordable;
poziva Komisijo, naj podpre programa za preprečevanje in zdravljenje porodnega kanala in zdravstvene oskrbe prizadetih deklet in žena;
Calls on the Commission to support programmes to prevent and cure obstetric fistula and care for the women and girls affected;
poziva k pobudam za omogočanje hitrega dostopa lokalnega prebivalstva do ustreznega ugotavljanja in določanja bolezni ter uporabo metod za varno zbiranje krvi, s čemer sta povezana ustrezno usposabljanje in infrastruktura; nadalje poziva k pobudam za spremljanje ključnih parametrov s področja zdravja in poudarja, kako zelo pomembno je, da programi cepljenja določajo uporabo takšnih medicinskih pripomočkov, ki jih ni mogoče ponovno uporabiti;
Calls for initiatives to provide accelerated local access to appropriate diagnostics and safe blood collection methods, with associated training and infrastructure, to monitor key health parameters, and stresses the importance of ensuring that all immunisation programmes mandate the use of medical technology that prevents re-use;
poziva Komisijo, naj zagotovi podporo krepitvi nacionalnih in mednarodnih programov za nadzor nad tobakom;
Invites the Commission to provide support for strengthening national and international tobacco control programmes;
meni, da so javno-zasebna partnerstva kot partnerstvo RBM, TB Alliance, IAVI, IPM, GAVI/The Vaccine Fund, MMV, DNDi in Institute for One Wolrd Health ter TDR bistvena za inovacije in boljšo izgradnjo zmogljivosti;
Believes that public-private partnerships such as the RBM Partnership, TB Alliance, IAVI, IPM, GAVI/The Vaccine Fund, MMV, DNDi and the Institute for One World Health together with TDR are key to innovation and capacity-building;
obžaluje pomanjkanje raziskav in razvoja na področju bolezni, ki zaradi pomanjkanja uspešnih trgov skoraj vedno prizadanejo revno prebivalstvo v državah v razvoju, in poudarja, da je treba stanje izboljšati z napori na mednarodni ravni;
Regrets the lack of R&D into diseases which almost exclusively affect poor people in developing countries, due to a lack of viable markets, and stresses that this must be corrected by international efforts;
poziva, da naj sedmi okvirni program vključi posebna navodila in financiranje za raziskave bolezni, ki prizadenejo prebivalce držav v razvoju;
Calls for the Seventh Framework Programme to include specific reference to and funding for research on illnesses that affect citizens of developing countries;
spodbuja Komisijo, naj nemudoma prične proučevati načine izvajanja specifičnih ukrepov za večjo fleksibilnost obstoječih in načrtovanih tematskih proračunskih postavk, kot tudi načinov, kako poenostaviti postopke in izboljšati sinergijo in doslednost političnih ukrepov, služb in programov Skupnosti v prizadevanjih za odpravo teh treh bolezni;
Encourages the Commission to examine as of now ways of implementing the concrete steps to be taken with regard to the flexibility of current and planned thematic budget lines and also to simplify procedures in order to improve the synergy and consistency of Community policies, services and programmes in the fight against the three diseases;
poziva Komisijo k sodelovanju s WHO, vključno pri TDR in pobudi za raziskovanje na področju cepiv, pri pripravi temeljnega razvojno-raziskovalnega programa, ki bo opredelil potrebe in prednostne naloge držav v razvoju;
Calls on the Commission to work with WHO, including through the TDR and the Initiative for Vaccine Research, to draw up an essential R&D agenda to define needs and priorities for the developing world;
izraža prepričanje, da mora ponovni pregled in registracija zdravil ustrezati prednostnim nalogam držav z endemičnimi boleznimi s posebnimi postopki za boljšo oceno razmerja med tveganjem in koristmi zdravil za zanemarjanje bolezni;
Believes that the review and registration of drugs should be relevant to the priorities of disease-endemic countries with specific procedures for better assessment of the risk-benefit ratio of drugs for neglected diseases;
poziva k boljšim delovnim pogojem za medicinsko osebje, ki dela v državah v razvoju, zagotavljanju ustrezne medicinske opreme in prenosu tehnologije; poziva k večjemu številu zdravnikov iz Evrope, ki bi sodelovali v programih izmenjave z državami v razvoju in obratno;
Calls for the improvement of working conditions for medical staff practising in developing countries, the provision of suitable medical equipment and transfer of technology; calls for an increase in exchange programmes of doctors from Europe to developing countries and vice versa;
poziva Komisijo, da podpre integrirane raziskovalne projekte, ki vključujejo celoten postopek prepoznavanja kemičnih snovi, dokler najučinkovitejša zdravila ne pridejo na trg;
Calls on the Commission to support integrated research projects involving the complete process of identification of chemicals through to the most effective being put on the market;
poziva, da se dejavnosti partnerstva EDCTP razširijo in vključijo druge zapostavljene bolezni in druge stopnje kliničnega razvoja (Stopnja I in IV);
Calls for the activities of the EDCTP to be broadened to include other neglected diseases and other phases of clinical development (Phase I and IV);
zahteva, da se mednarodni standardi, ki veljajo za etične raziskave, kot so denimo zastavljeni v Helsinški deklaraciji, uporabljajo v vseh državah;
Demands that international standards for ethical research, such as those set out in the Declaration of Helsinki, be applied in all countries;
poziva k sodelovanju s farmacevtsko industrijo na področju bolezni, povezanih z revščino; da se z novim okvirnim predlogom za raziskave in razvoj teh bolezni zagotovijo spodbude za naložbe, med njimi podpora pri pripravi protokolov, oprostitive plačil pristojbin, davčne olajšave, subvencije, nagrade za inovacije, pomoč pri vpisu zdravil na prednostni seznam, vnaprejšnje nakupne obveznosti in delni prenos patentnih pravic za zdravila; poziva še k uporabi pristopa, ki temelji na dejanskih potrebah;
Calls for collaboration with the pharmaceutical industry on poverty diseases, with a new framework proposal for R&D in such diseases, to provide incentives for investment, including protocol assistance, fee waivers, tax credits, subsidies, innovation prizes, assistance for prequalification, advance purchase commitments and partial transfer of patent rights to drugs; and calls also for a "needs based approach";
poudarja, da sta izobraževanje in družinsko načrtovanje enako pomembna kot zagotavljanje učinkovitih zdravil;
Stresses that education and family planning are as important as the provision of effective drugs;
poziva k določitvi obveznosti ali spodbud za farmacevtsko industrijo, da neposredno ali z javnimi programi del dobička ponovno vloži v raziskave in razvoj zapostavljenih bolezni;
Calls for an obligation on or incentive to the pharmaceutical industry to reinvest a percentage of profits into neglected disease R&D, either directly or through public programmes;
v okviru Komisije WHO za intelektualno lastnino, inovacije in zdravje poziva k oblikovanju novega mednarodnega sporazuma za raziskave in razvoj s področja zdravja, ki bo vseboval minimalne obveznosti glede spodbujanja raziskav in razvoja, mehanizme za določanje prednostnih nalog in oceno sistema tržnih posojil za naložbe v posamezne projekte;
Urges, in the context of the WHO Commission on Intellectual Property, Innovation and Health, a new global medical R&D treaty, including minimum obligations to support R&D, priority setting mechanisms and consideration of a system of tradeable credits for investments in particular projects;
meni, da bi bilo treba izgradnjo lokalnih zmogljivosti raziskav in razvoja ter proizvodne zmogljivosti s prenosom in delitvijo tehnologije spodbujati z razvojno politiko;
Believes that building of local R&D and production capacity through technology transfer and sharing should be promoted through development policies;